APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oral Hypoglycemic Agents and Insulin Injection

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Oral Hypoglycemic Agents and Insulin Injection Industry Growth and Trends Forecast to 2032

29 December 2025123 pages

Choose your research edition.

Industry ResearchOral Hypoglycemic Agents and Insulin Injection Industry Research Report 2026151 pages · $2,950 USDIndustry Growth & TrendsGlobal Oral Hypoglycemic Agents and Insulin Injection Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Oral Hypoglycemic Agents and Insulin Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oral Hypoglycemic Agents and Insulin Injection Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Oral Hypoglycemic Agents and Insulin Injection Market Analysis and Forecast 2026-2032217 pages · $4,950 USD

Market perspective

The global Oral Hypoglycemic Agents and Insulin Injection market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Oral Hypoglycemic Agents and Insulin Injection is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Oral Hypoglycemic Agents and Insulin Injection is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Oral Hypoglycemic Agents and Insulin Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Oral Hypoglycemic Agents and Insulin Injection include YZJ Group, Takeda Pharmaceuticals, Tonghua Dongbao Pharmaceutical, Sichuan Luye Pharma, Sanofi, Johnson & Johnson, Merck, The United Laboratories International Holdings and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Oral Hypoglycemic Agents and Insulin Injection market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Oral Hypoglycemic Agents and Insulin Injection market size, estimates, and forecasts are presented in terms of sales volume (M Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Oral Hypoglycemic Agents and Insulin Injection market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Oral Hypoglycemic Agents and Insulin Injection.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Oral Hypoglycemic Agents and Insulin Injection market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Oral Hypoglycemic Agents and Insulin Injection Market by Company

YZJ Group

Takeda Pharmaceuticals

Tonghua Dongbao Pharmaceutical

Sichuan Luye Pharma

Sanofi

Johnson & Johnson

Merck

The United Laboratories International Holdings

Pfizer

Huadong Medicine

Gan and Lee Pharmaceuticals

AstraZeneca

Taisho Pharmaceutical

Servier Laboratories

Novo Nordisk

GlaxoSmithKline

Eli Lilly and Company

Chugai Pharmaceutical

Bristol Myers Squibb

Boehringer Ingelheim

Astellas

Oral Hypoglycemic Agents and Insulin Injection Segment by Type

Oral Hypoglycemic Agents

Insulin Injection

Oral Hypoglycemic Agents and Insulin Injection Segment by Application

E-commerce and Internet Medical Care

Offline Retail Pharmacy

Hospitals and Clinics

Oral Hypoglycemic Agents and Insulin Injection Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Hypoglycemic Agents and Insulin Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oral Hypoglycemic Agents and Insulin Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Hypoglycemic Agents and Insulin Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Oral Hypoglycemic Agents and Insulin Injection manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Oral Hypoglycemic Agents and Insulin Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Oral Hypoglycemic Agents Table 2. Major Company of Insulin Injection Table 3. Global Oral Hypoglycemic Agents and Insulin Injection Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Oral Hypoglycemic Agents and Insulin Injection Sales by Type (2021-2026) & (M Units) Table 5. Global Oral Hypoglycemic Agents and Insulin Injection Sales Market Share in Volume by Type (2021-2026) Table 6. Global Oral Hypoglycemic Agents and Insulin Injection Sales by Type (2021-2026) & (US$ Million) Table 7. Global Oral Hypoglycemic Agents and Insulin Injection Sales Market Share in Value by Type (2021-2026) Table 8. Global Oral Hypoglycemic Agents and Insulin Injection Price by Type (2021-2026) & (US$/Unit) Table 9. Global Oral Hypoglycemic Agents and Insulin Injection Sales by Type (2027-2032) & (M Units) Table 10. Global Oral Hypoglycemic Agents and Insulin Injection Sales Market Share in Volume by Type (2027-2032) Table 11. Global Oral Hypoglycemic Agents and Insulin Injection Sales by Type (2027-2032) & (US$ Million) Table 12. Global Oral Hypoglycemic Agents and Insulin Injection Sales Market Share in Value by Type (2027-2032) Table 13. Global Oral Hypoglycemic Agents and Insulin Injection Price by Type (2027-2032) & (US$/Unit) Table 14. North America Oral Hypoglycemic Agents and Insulin Injection Sales by Type (2021-2026) & (M Units) Table 15. North America Oral Hypoglycemic Agents and Insulin Injection Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Oral Hypoglycemic Agents and Insulin Injection Sales by Type (2021-2026) & (M Units) Table 17. Europe Oral Hypoglycemic Agents and Insulin Injection Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Oral Hypoglycemic Agents and Insulin Injection Sales by Type (2021-2026) & (M Units) Table 19. Asia-Pacific Oral Hypoglycemic Agents and Insulin Injection Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Oral Hypoglycemic Agents and Insulin Injection Sales by Type (2021-2026) & (M Units) Table 21. Latin America Oral Hypoglycemic Agents and Insulin Injection Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Sales by Type (2021-2026) & (M Units) Table 23. Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Sales by Type (2021-2026) & (US$ Million) Table 24. Oral Hypoglycemic Agents and Insulin Injection Industry Trends Table 25. Oral Hypoglycemic Agents and Insulin Injection Industry Drivers Table 26. Oral Hypoglycemic Agents and Insulin Injection Industry Opportunities and Challenges Table 27. Oral Hypoglycemic Agents and Insulin Injection Industry Restraints Table 28. Global Oral Hypoglycemic Agents and Insulin Injection Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Oral Hypoglycemic Agents and Insulin Injection Revenue Market Share by Company (2021-2026) Table 30. Global Oral Hypoglycemic Agents and Insulin Injection Sales by Company (2021-2026) & (M Units) Table 31. Global Oral Hypoglycemic Agents and Insulin Injection Sales Share by Company (2021-2026) Table 32. Global Oral Hypoglycemic Agents and Insulin Injection Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Oral Hypoglycemic Agents and Insulin Injection Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Oral Hypoglycemic Agents and Insulin Injection Major Company Production Sites and Headquarters Table 35. Global Oral Hypoglycemic Agents and Insulin Injection Company, Product Type & Application Table 36. Global Oral Hypoglycemic Agents and Insulin Injection Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Oral Hypoglycemic Agents and Insulin Injection by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Oral Hypoglycemic Agents and Insulin Injection Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Oral Hypoglycemic Agents and Insulin Injection Sales by Region (2021-2026) & (M Units) Table 41. Global Oral Hypoglycemic Agents and Insulin Injection Sales Market Share in Volume by Region (2021-2026) Table 42. Global Oral Hypoglycemic Agents and Insulin Injection Sales by Region (2021-2026) & (US$ Million) Table 43. Global Oral Hypoglycemic Agents and Insulin Injection Sales Market Share in Value by Region (2021-2026) Table 44. Global Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Oral Hypoglycemic Agents and Insulin Injection Sales by Region (2027-2032) & (M Units) Table 46. Global Oral Hypoglycemic Agents and Insulin Injection Sales Market Share in Volume by Region (2027-2032) Table 47. Global Oral Hypoglycemic Agents and Insulin Injection Sales by Region (2027-2032) & (US$ Million) Table 48. Global Oral Hypoglycemic Agents and Insulin Injection Sales Market Share in Value by Region (2027-2032) Table 49. Global Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Oral Hypoglycemic Agents and Insulin Injection Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Oral Hypoglycemic Agents and Insulin Injection Sales by Application (2021-2026) & (M Units) Table 52. Global Oral Hypoglycemic Agents and Insulin Injection Sales Market Share in Volume by Application (2021-2026) Table 53. Global Oral Hypoglycemic Agents and Insulin Injection Sales by Application (2021-2026) & (US$ Million) Table 54. Global Oral Hypoglycemic Agents and Insulin Injection Sales Market Share in Value by Application (2021-2026) Table 55. Global Oral Hypoglycemic Agents and Insulin Injection Price by Application (2021-2026) & (US$/Unit) Table 56. Global Oral Hypoglycemic Agents and Insulin Injection Sales by Application (2027-2032) & (M Units) Table 57. Global Oral Hypoglycemic Agents and Insulin Injection Sales Market Share in Volume by Application (2027-2032) Table 58. Global Oral Hypoglycemic Agents and Insulin Injection Sales by Application (2027-2032) & (US$ Million) Table 59. Global Oral Hypoglycemic Agents and Insulin Injection Sales Market Share in Value by Application (2027-2032) Table 60. Global Oral Hypoglycemic Agents and Insulin Injection Price by Application (2027-2032) & (US$/Unit) Table 61. North America Oral Hypoglycemic Agents and Insulin Injection Sales by Application (2021-2026) & (M Units) Table 62. North America Oral Hypoglycemic Agents and Insulin Injection Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Oral Hypoglycemic Agents and Insulin Injection Sales by Application (2021-2026) & (M Units) Table 64. Europe Oral Hypoglycemic Agents and Insulin Injection Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Oral Hypoglycemic Agents and Insulin Injection Sales by Application (2021-2026) & (M Units) Table 66. Asia-Pacific Oral Hypoglycemic Agents and Insulin Injection Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Oral Hypoglycemic Agents and Insulin Injection Sales by Application (2021-2026) & (M Units) Table 68. Latin America Oral Hypoglycemic Agents and Insulin Injection Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Sales by Application (2021-2026) & (M Units) Table 70. Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Sales by Application (2021-2026) & (US$ Million) Table 71. YZJ Group Company Information Table 72. YZJ Group Business Overview Table 73. YZJ Group Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. YZJ Group Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 75. YZJ Group Recent Development Table 76. Takeda Pharmaceuticals Company Information Table 77. Takeda Pharmaceuticals Business Overview Table 78. Takeda Pharmaceuticals Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Takeda Pharmaceuticals Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 80. Takeda Pharmaceuticals Recent Development Table 81. Tonghua Dongbao Pharmaceutical Company Information Table 82. Tonghua Dongbao Pharmaceutical Business Overview Table 83. Tonghua Dongbao Pharmaceutical Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Tonghua Dongbao Pharmaceutical Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 85. Tonghua Dongbao Pharmaceutical Recent Development Table 86. Sichuan Luye Pharma Company Information Table 87. Sichuan Luye Pharma Business Overview Table 88. Sichuan Luye Pharma Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Sichuan Luye Pharma Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 90. Sichuan Luye Pharma Recent Development Table 91. Sanofi Company Information Table 92. Sanofi Business Overview Table 93. Sanofi Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Sanofi Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 95. Sanofi Recent Development Table 96. Johnson & Johnson Company Information Table 97. Johnson & Johnson Business Overview Table 98. Johnson & Johnson Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Johnson & Johnson Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 100. Johnson & Johnson Recent Development Table 101. Merck Company Information Table 102. Merck Business Overview Table 103. Merck Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Merck Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 105. Merck Recent Development Table 106. The United Laboratories International Holdings Company Information Table 107. The United Laboratories International Holdings Business Overview Table 108. The United Laboratories International Holdings Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. The United Laboratories International Holdings Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 110. The United Laboratories International Holdings Recent Development Table 111. Pfizer Company Information Table 112. Pfizer Business Overview Table 113. Pfizer Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Pfizer Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 115. Pfizer Recent Development Table 116. Huadong Medicine Company Information Table 117. Huadong Medicine Business Overview Table 118. Huadong Medicine Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Huadong Medicine Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 120. Huadong Medicine Recent Development Table 121. Gan and Lee Pharmaceuticals Company Information Table 122. Gan and Lee Pharmaceuticals Business Overview Table 123. Gan and Lee Pharmaceuticals Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Gan and Lee Pharmaceuticals Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 125. Gan and Lee Pharmaceuticals Recent Development Table 126. AstraZeneca Company Information Table 127. AstraZeneca Business Overview Table 128. AstraZeneca Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. AstraZeneca Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 130. AstraZeneca Recent Development Table 131. Taisho Pharmaceutical Company Information Table 132. Taisho Pharmaceutical Business Overview Table 133. Taisho Pharmaceutical Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Taisho Pharmaceutical Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 135. Taisho Pharmaceutical Recent Development Table 136. Servier Laboratories Company Information Table 137. Servier Laboratories Business Overview Table 138. Servier Laboratories Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Servier Laboratories Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 140. Servier Laboratories Recent Development Table 141. Novo Nordisk Company Information Table 142. Novo Nordisk Business Overview Table 143. Novo Nordisk Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. Novo Nordisk Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 145. Novo Nordisk Recent Development Table 146. GlaxoSmithKline Company Information Table 147. GlaxoSmithKline Business Overview Table 148. GlaxoSmithKline Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 149. GlaxoSmithKline Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 150. GlaxoSmithKline Recent Development Table 151. Eli Lilly and Company Company Information Table 152. Eli Lilly and Company Business Overview Table 153. Eli Lilly and Company Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 154. Eli Lilly and Company Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 155. Eli Lilly and Company Recent Development Table 156. Chugai Pharmaceutical Company Information Table 157. Chugai Pharmaceutical Business Overview Table 158. Chugai Pharmaceutical Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 159. Chugai Pharmaceutical Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 160. Chugai Pharmaceutical Recent Development Table 161. Bristol Myers Squibb Company Information Table 162. Bristol Myers Squibb Business Overview Table 163. Bristol Myers Squibb Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 164. Bristol Myers Squibb Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 165. Bristol Myers Squibb Recent Development Table 166. Boehringer Ingelheim Company Information Table 167. Boehringer Ingelheim Business Overview Table 168. Boehringer Ingelheim Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 169. Boehringer Ingelheim Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 170. Boehringer Ingelheim Recent Development Table 171. Astellas Company Information Table 172. Astellas Business Overview Table 173. Astellas Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 174. Astellas Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 175. Astellas Recent Development Table 176. North America Oral Hypoglycemic Agents and Insulin Injection Market Size Growth Rate (CAGR) by Country (M Units): 2021 VS 2025 VS 2032 Table 177. North America Oral Hypoglycemic Agents and Insulin Injection Sales by Country (2021-2026) & (M Units) Table 178. North America Oral Hypoglycemic Agents and Insulin Injection Sales Market Share by Country (2021-2026) Table 179. North America Oral Hypoglycemic Agents and Insulin Injection Sales Forecast by Country (2027-2032) & (M Units) Table 180. North America Oral Hypoglycemic Agents and Insulin Injection Sales Market Share Forecast by Country (2027-2032) Table 181. North America Oral Hypoglycemic Agents and Insulin Injection Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 182. North America Oral Hypoglycemic Agents and Insulin Injection Market Size by Country (2021-2026) & (US$ Million) Table 183. North America Oral Hypoglycemic Agents and Insulin Injection Market Share by Country (2021-2026) Table 184. North America Oral Hypoglycemic Agents and Insulin Injection Market Size Forecast by Country (2027-2032) & (US$ Million) Table 185. North America Oral Hypoglycemic Agents and Insulin Injection Market Share Forecast by Country (2027-2032) Table 186. Europe Oral Hypoglycemic Agents and Insulin Injection Market Size Growth Rate (CAGR) by Country (M Units): 2021 VS 2025 VS 2032 Table 187. Europe Oral Hypoglycemic Agents and Insulin Injection Sales by Country (2021-2026) & (M Units) Table 188. Europe Oral Hypoglycemic Agents and Insulin Injection Sales Market Share by Country (2021-2026) Table 189. Europe Oral Hypoglycemic Agents and Insulin Injection Sales Forecast by Country (2027-2032) & (M Units) Table 190. Europe Oral Hypoglycemic Agents and Insulin Injection Sales Market Share Forecast by Country (2027-2032) Table 191. Europe Oral Hypoglycemic Agents and Insulin Injection Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 192. Europe Oral Hypoglycemic Agents and Insulin Injection Market Size by Country (2021-2026) & (US$ Million) Table 193. Europe Oral Hypoglycemic Agents and Insulin Injection Market Share by Country (2021-2026) Table 194. Europe Oral Hypoglycemic Agents and Insulin Injection Market Size Forecast by Country (2027-2032) & (US$ Million) Table 195. Europe Oral Hypoglycemic Agents and Insulin Injection Market Share Forecast by Country (2027-2032) Table 196. Asia-Pacific Oral Hypoglycemic Agents and Insulin Injection Market Size Growth Rate (CAGR) by Country (M Units): 2021 VS 2025 VS 2032 Table 197. Asia-Pacific Oral Hypoglycemic Agents and Insulin Injection Sales by Country (2021-2026) & (M Units) Table 198. Asia-Pacific Oral Hypoglycemic Agents and Insulin Injection Sales Market Share by Country (2021-2026) Table 199. Asia-Pacific Oral Hypoglycemic Agents and Insulin Injection Sales Forecast by Country (2027-2032) & (M Units) Table 200. Asia-Pacific Oral Hypoglycemic Agents and Insulin Injection Sales Market Share Forecast by Country (2027-2032) Table 201. Asia-Pacific Oral Hypoglycemic Agents and Insulin Injection Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 202. Asia-Pacific Oral Hypoglycemic Agents and Insulin Injection Market Size by Country (2021-2026) & (US$ Million) Table 203. Asia-Pacific Oral Hypoglycemic Agents and Insulin Injection Market Share by Country (2021-2026) Table 204. Asia-Pacific Oral Hypoglycemic Agents and Insulin Injection Market Size Forecast by Country (2027-2032) & (US$ Million) Table 205. Asia-Pacific Oral Hypoglycemic Agents and Insulin Injection Market Share Forecast by Country (2027-2032) Table 206. Latin America Oral Hypoglycemic Agents and Insulin Injection Market Size Growth Rate (CAGR) by Country (M Units): 2021 VS 2025 VS 2032 Table 207. Latin America Oral Hypoglycemic Agents and Insulin Injection Sales by Country (2021-2026) & (M Units) Table 208. Latin America Oral Hypoglycemic Agents and Insulin Injection Sales Market Share by Country (2021-2026) Table 209. Latin America Oral Hypoglycemic Agents and Insulin Injection Sales Forecast by Country (2027-2032) & (M Units) Table 210. Latin America Oral Hypoglycemic Agents and Insulin Injection Sales Market Share Forecast by Country (2027-2032) Table 211. Latin America Oral Hypoglycemic Agents and Insulin Injection Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 212. Latin America Oral Hypoglycemic Agents and Insulin Injection Market Size by Country (2021-2026) & (US$ Million) Table 213. Latin America Oral Hypoglycemic Agents and Insulin Injection Market Share by Country (2021-2026) Table 214. Latin America Oral Hypoglycemic Agents and Insulin Injection Market Size Forecast by Country (2027-2032) & (US$ Million) Table 215. Latin America Oral Hypoglycemic Agents and Insulin Injection Market Share Forecast by Country (2027-2032) Table 216. Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Market Size Growth Rate (CAGR) by Country (M Units): 2021 VS 2025 VS 2032 Table 217. Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Sales by Country (2021-2026) & (M Units) Table 218. Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Sales Market Share by Country (2021-2026) Table 219. Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Sales Forecast by Country (2027-2032) & (M Units) Table 220. Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Sales Market Share Forecast by Country (2027-2032) Table 221. Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 222. Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Market Size by Country (2021-2026) & (US$ Million) Table 223. Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Market Share by Country (2021-2026) Table 224. Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Market Size Forecast by Country (2027-2032) & (US$ Million) Table 225. Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Market Share Forecast by Country (2027-2032) Table 226. Key Raw Materials Table 227. Raw Materials Key Suppliers Table 228. Oral Hypoglycemic Agents and Insulin Injection Distributors List Table 229. Oral Hypoglycemic Agents and Insulin Injection Customers List Table 230. Research Programs/Design for This Report Table 231. Authors List of This Report Table 232. Secondary Sources Table 233. Primary Sources List of Figures Figure 1. Oral Hypoglycemic Agents and Insulin Injection Image Figure 2. Global Oral Hypoglycemic Agents and Insulin Injection Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oral Hypoglycemic Agents and Insulin Injection Market Size (2021-2032) & (US$ Million) Figure 4. Global Oral Hypoglycemic Agents and Insulin Injection Sales (2021-2032) & (M Units) Figure 5. Oral Hypoglycemic Agents Image Figure 6. Global Oral Hypoglycemic Agents Sales YoY Growth (2021-2032) & (M Units) Figure 7. Insulin Injection Image Figure 8. Global Insulin Injection Sales YoY Growth (2021-2032) & (M Units) Figure 9. Global Oral Hypoglycemic Agents and Insulin Injection Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Oral Hypoglycemic Agents and Insulin Injection Market Share by Type 2025 VS 2032 Figure 11. North America Oral Hypoglycemic Agents and Insulin Injection Sales Market Share in Volume by Type in 2025 Figure 12. North America Oral Hypoglycemic Agents and Insulin Injection Sales Market Share in Value by Type in 2025 Figure 13. Europe Oral Hypoglycemic Agents and Insulin Injection Sales Market Share in Volume by Type in 2025 Figure 14. Europe Oral Hypoglycemic Agents and Insulin Injection Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Oral Hypoglycemic Agents and Insulin Injection Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Oral Hypoglycemic Agents and Insulin Injection Sales Market Share in Value by Type in 2025 Figure 17. Latin America Oral Hypoglycemic Agents and Insulin Injection Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Oral Hypoglycemic Agents and Insulin Injection Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Oral Hypoglycemic Agents and Insulin Injection Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. E-commerce and Internet Medical Care Image Figure 24. Global E-commerce and Internet Medical Care Sales YoY Growth (2021-2032) & (M Units) Figure 25. Offline Retail Pharmacy Image Figure 26. Global Offline Retail Pharmacy Sales YoY Growth (2021-2032) & (M Units) Figure 27. Hospitals and Clinics Image Figure 28. Global Hospitals and Clinics Sales YoY Growth (2021-2032) & (M Units) Figure 29. Global Oral Hypoglycemic Agents and Insulin Injection Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Oral Hypoglycemic Agents and Insulin Injection Market Share by Application 2025 VS 2032 Figure 31. North America Oral Hypoglycemic Agents and Insulin Injection Sales Market Share in Volume by Application in 2025 Figure 32. North America Oral Hypoglycemic Agents and Insulin Injection Sales Market Share in Value by Application in 2025 Figure 33. Europe Oral Hypoglycemic Agents and Insulin Injection Sales Market Share in Volume by Application in 2025 Figure 34. Europe Oral Hypoglycemic Agents and Insulin Injection Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Oral Hypoglycemic Agents and Insulin Injection Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Oral Hypoglycemic Agents and Insulin Injection Sales Market Share in Value by Application in 2025 Figure 37. Latin America Oral Hypoglycemic Agents and Insulin Injection Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Oral Hypoglycemic Agents and Insulin Injection Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Sales Market Share in Value by Application in 2025 Figure 41. North America Oral Hypoglycemic Agents and Insulin Injection Sales by Country: 2021 VS 2025 VS 2032 (M Units) Figure 42. North America Oral Hypoglycemic Agents and Insulin Injection Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Oral Hypoglycemic Agents and Insulin Injection Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Oral Hypoglycemic Agents and Insulin Injection Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Oral Hypoglycemic Agents and Insulin Injection Sales by Country: 2021 VS 2025 VS 2032 (M Units) Figure 46. Europe Oral Hypoglycemic Agents and Insulin Injection Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Oral Hypoglycemic Agents and Insulin Injection Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Oral Hypoglycemic Agents and Insulin Injection Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Oral Hypoglycemic Agents and Insulin Injection Sales by Country: 2021 VS 2025 VS 2032 (M Units) Figure 50. Asia-Pacific Oral Hypoglycemic Agents and Insulin Injection Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Oral Hypoglycemic Agents and Insulin Injection Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Oral Hypoglycemic Agents and Insulin Injection Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Oral Hypoglycemic Agents and Insulin Injection Sales by Country: 2021 VS 2025 VS 2032 (M Units) Figure 54. Latin America Oral Hypoglycemic Agents and Insulin Injection Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Oral Hypoglycemic Agents and Insulin Injection Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Oral Hypoglycemic Agents and Insulin Injection Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Sales by Country: 2021 VS 2025 VS 2032 (M Units) Figure 58. Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Oral Hypoglycemic Agents and Insulin Injection Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Oral Hypoglycemic Agents and Insulin Injection Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Oral Hypoglycemic Agents
  • Insulin Injection
Applications
  • E-commerce and Internet Medical Care
  • Offline Retail Pharmacy
  • Hospitals and Clinics
Companies covered
  • YZJ Group
  • Takeda Pharmaceuticals
  • Tonghua Dongbao Pharmaceutical
  • Sichuan Luye Pharma
  • Sanofi
  • Johnson & Johnson
  • Merck
  • The United Laboratories International Holdings
  • Pfizer
  • Huadong Medicine
  • Gan and Lee Pharmaceuticals
  • AstraZeneca
  • Taisho Pharmaceutical
  • Servier Laboratories
  • Novo Nordisk
  • GlaxoSmithKline
  • Eli Lilly and Company
  • Chugai Pharmaceutical
  • Bristol Myers Squibb
  • Boehringer Ingelheim
  • Astellas

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Oral Hypoglycemic Agents and Insulin Injection Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Oral Hypoglycemic Agents and Insulin Injection Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Oral Hypoglycemic Agents and Insulin Injection Market by Type
  6. 1.3.1 Oral Hypoglycemic Agents
  7. 1.3.2 Insulin Injection
  8. 1.4 Global Oral Hypoglycemic Agents and Insulin Injection Market Size by Type
  9. 1.4.1 Global Oral Hypoglycemic Agents and Insulin Injection Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Oral Hypoglycemic Agents and Insulin Injection Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Oral Hypoglycemic Agents and Insulin Injection Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Oral Hypoglycemic Agents and Insulin Injection Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Oral Hypoglycemic Agents and Insulin Injection Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Oral Hypoglycemic Agents and Insulin Injection Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Oral Hypoglycemic Agents and Insulin Injection Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Oral Hypoglycemic Agents and Insulin Injection Industry Trends
  2. 2.2 Oral Hypoglycemic Agents and Insulin Injection Industry Drivers
  3. 2.3 Oral Hypoglycemic Agents and Insulin Injection Industry Opportunities and Challenges
  4. 2.4 Oral Hypoglycemic Agents and Insulin Injection Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Oral Hypoglycemic Agents and Insulin Injection Revenue (2021-2026)
  2. 3.2 Global Top Players by Oral Hypoglycemic Agents and Insulin Injection Sales (2021-2026)
  3. 3.3 Global Top Players by Oral Hypoglycemic Agents and Insulin Injection Price (2021-2026)
  4. 3.4 Global Oral Hypoglycemic Agents and Insulin Injection Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Oral Hypoglycemic Agents and Insulin Injection Major Company Production Sites & Headquarters
  6. 3.6 Global Oral Hypoglycemic Agents and Insulin Injection Company, Product Type & Application
  7. 3.7 Global Oral Hypoglycemic Agents and Insulin Injection Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Oral Hypoglycemic Agents and Insulin Injection Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Oral Hypoglycemic Agents and Insulin Injection Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Oral Hypoglycemic Agents and Insulin Injection Tier 1, Tier 2, and Tier 3
4 Oral Hypoglycemic Agents and Insulin Injection Regional Status and Outlook
  1. 4.1 Global Oral Hypoglycemic Agents and Insulin Injection Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Oral Hypoglycemic Agents and Insulin Injection Historic Market Size by Region
  3. 4.2.1 Global Oral Hypoglycemic Agents and Insulin Injection Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Oral Hypoglycemic Agents and Insulin Injection Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Oral Hypoglycemic Agents and Insulin Injection Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Oral Hypoglycemic Agents and Insulin Injection Forecasted Market Size by Region
  7. 4.3.1 Global Oral Hypoglycemic Agents and Insulin Injection Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Oral Hypoglycemic Agents and Insulin Injection Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Oral Hypoglycemic Agents and Insulin Injection Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Oral Hypoglycemic Agents and Insulin Injection by Application
  1. 5.1 Oral Hypoglycemic Agents and Insulin Injection Market by Application
  2. 5.1.1 E-commerce and Internet Medical Care
  3. 5.1.2 Offline Retail Pharmacy
  4. 5.1.3 Hospitals and Clinics
  5. 5.2 Global Oral Hypoglycemic Agents and Insulin Injection Market Size by Application
  6. 5.2.1 Global Oral Hypoglycemic Agents and Insulin Injection Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Oral Hypoglycemic Agents and Insulin Injection Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Oral Hypoglycemic Agents and Insulin Injection Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Oral Hypoglycemic Agents and Insulin Injection Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Oral Hypoglycemic Agents and Insulin Injection Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Oral Hypoglycemic Agents and Insulin Injection Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Oral Hypoglycemic Agents and Insulin Injection Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 YZJ Group
  2. 6.1.1 YZJ Group Company Information
  3. 6.1.2 YZJ Group Business Overview
  4. 6.1.3 YZJ Group Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 YZJ Group Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  6. 6.1.5 YZJ Group Recent Developments
  7. 6.2 Takeda Pharmaceuticals
  8. 6.2.1 Takeda Pharmaceuticals Company Information
  9. 6.2.2 Takeda Pharmaceuticals Business Overview
  10. 6.2.3 Takeda Pharmaceuticals Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Takeda Pharmaceuticals Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  12. 6.2.5 Takeda Pharmaceuticals Recent Developments
  13. 6.3 Tonghua Dongbao Pharmaceutical
  14. 6.3.1 Tonghua Dongbao Pharmaceutical Company Information
  15. 6.3.2 Tonghua Dongbao Pharmaceutical Business Overview
  16. 6.3.3 Tonghua Dongbao Pharmaceutical Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Tonghua Dongbao Pharmaceutical Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  18. 6.3.5 Tonghua Dongbao Pharmaceutical Recent Developments
  19. 6.4 Sichuan Luye Pharma
  20. 6.4.1 Sichuan Luye Pharma Company Information
  21. 6.4.2 Sichuan Luye Pharma Business Overview
  22. 6.4.3 Sichuan Luye Pharma Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Sichuan Luye Pharma Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  24. 6.4.5 Sichuan Luye Pharma Recent Developments
  25. 6.5 Sanofi
  26. 6.5.1 Sanofi Company Information
  27. 6.5.2 Sanofi Business Overview
  28. 6.5.3 Sanofi Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Sanofi Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  30. 6.5.5 Sanofi Recent Developments
  31. 6.6 Johnson & Johnson
  32. 6.6.1 Johnson & Johnson Company Information
  33. 6.6.2 Johnson & Johnson Business Overview
  34. 6.6.3 Johnson & Johnson Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Johnson & Johnson Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  36. 6.6.5 Johnson & Johnson Recent Developments
  37. 6.7 Merck
  38. 6.7.1 Merck Company Information
  39. 6.7.2 Merck Business Overview
  40. 6.7.3 Merck Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Merck Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  42. 6.7.5 Merck Recent Developments
  43. 6.8 The United Laboratories International Holdings
  44. 6.8.1 The United Laboratories International Holdings Company Information
  45. 6.8.2 The United Laboratories International Holdings Business Overview
  46. 6.8.3 The United Laboratories International Holdings Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 The United Laboratories International Holdings Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  48. 6.8.5 The United Laboratories International Holdings Recent Developments
  49. 6.9 Pfizer
  50. 6.9.1 Pfizer Company Information
  51. 6.9.2 Pfizer Business Overview
  52. 6.9.3 Pfizer Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Pfizer Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  54. 6.9.5 Pfizer Recent Developments
  55. 6.10 Huadong Medicine
  56. 6.10.1 Huadong Medicine Company Information
  57. 6.10.2 Huadong Medicine Business Overview
  58. 6.10.3 Huadong Medicine Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Huadong Medicine Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  60. 6.10.5 Huadong Medicine Recent Developments
  61. 6.11 Gan and Lee Pharmaceuticals
  62. 6.11.1 Gan and Lee Pharmaceuticals Company Information
  63. 6.11.2 Gan and Lee Pharmaceuticals Business Overview
  64. 6.11.3 Gan and Lee Pharmaceuticals Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Gan and Lee Pharmaceuticals Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  66. 6.11.5 Gan and Lee Pharmaceuticals Recent Developments
  67. 6.12 AstraZeneca
  68. 6.12.1 AstraZeneca Company Information
  69. 6.12.2 AstraZeneca Business Overview
  70. 6.12.3 AstraZeneca Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 AstraZeneca Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  72. 6.12.5 AstraZeneca Recent Developments
  73. 6.13 Taisho Pharmaceutical
  74. 6.13.1 Taisho Pharmaceutical Company Information
  75. 6.13.2 Taisho Pharmaceutical Business Overview
  76. 6.13.3 Taisho Pharmaceutical Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Taisho Pharmaceutical Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  78. 6.13.5 Taisho Pharmaceutical Recent Developments
  79. 6.14 Servier Laboratories
  80. 6.14.1 Servier Laboratories Company Information
  81. 6.14.2 Servier Laboratories Business Overview
  82. 6.14.3 Servier Laboratories Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Servier Laboratories Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  84. 6.14.5 Servier Laboratories Recent Developments
  85. 6.15 Novo Nordisk
  86. 6.15.1 Novo Nordisk Company Information
  87. 6.15.2 Novo Nordisk Business Overview
  88. 6.15.3 Novo Nordisk Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Novo Nordisk Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  90. 6.15.5 Novo Nordisk Recent Developments
  91. 6.16 GlaxoSmithKline
  92. 6.16.1 GlaxoSmithKline Company Information
  93. 6.16.2 GlaxoSmithKline Business Overview
  94. 6.16.3 GlaxoSmithKline Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 GlaxoSmithKline Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  96. 6.16.5 GlaxoSmithKline Recent Developments
  97. 6.17 Eli Lilly and Company
  98. 6.17.1 Eli Lilly and Company Company Information
  99. 6.17.2 Eli Lilly and Company Business Overview
  100. 6.17.3 Eli Lilly and Company Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Eli Lilly and Company Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  102. 6.17.5 Eli Lilly and Company Recent Developments
  103. 6.18 Chugai Pharmaceutical
  104. 6.18.1 Chugai Pharmaceutical Company Information
  105. 6.18.2 Chugai Pharmaceutical Business Overview
  106. 6.18.3 Chugai Pharmaceutical Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 Chugai Pharmaceutical Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  108. 6.18.5 Chugai Pharmaceutical Recent Developments
  109. 6.19 Bristol Myers Squibb
  110. 6.19.1 Bristol Myers Squibb Company Information
  111. 6.19.2 Bristol Myers Squibb Business Overview
  112. 6.19.3 Bristol Myers Squibb Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 Bristol Myers Squibb Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  114. 6.19.5 Bristol Myers Squibb Recent Developments
  115. 6.20 Boehringer Ingelheim
  116. 6.20.1 Boehringer Ingelheim Company Information
  117. 6.20.2 Boehringer Ingelheim Business Overview
  118. 6.20.3 Boehringer Ingelheim Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue and Gross Margin (2021-2026)
  119. 6.20.4 Boehringer Ingelheim Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  120. 6.20.5 Boehringer Ingelheim Recent Developments
  121. 6.21 Astellas
  122. 6.21.1 Astellas Company Information
  123. 6.21.2 Astellas Business Overview
  124. 6.21.3 Astellas Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue and Gross Margin (2021-2026)
  125. 6.21.4 Astellas Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  126. 6.21.5 Astellas Recent Developments
7 North America by Country
  1. 7.1 North America Oral Hypoglycemic Agents and Insulin Injection Sales by Country
  2. 7.1.1 North America Oral Hypoglycemic Agents and Insulin Injection Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Oral Hypoglycemic Agents and Insulin Injection Sales by Country (2021-2026)
  4. 7.1.3 North America Oral Hypoglycemic Agents and Insulin Injection Sales Forecast by Country (2027-2032)
  5. 7.2 North America Oral Hypoglycemic Agents and Insulin Injection Market Size by Country
  6. 7.2.1 North America Oral Hypoglycemic Agents and Insulin Injection Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Oral Hypoglycemic Agents and Insulin Injection Market Size by Country (2021-2026)
  8. 7.2.3 North America Oral Hypoglycemic Agents and Insulin Injection Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Oral Hypoglycemic Agents and Insulin Injection Sales by Country
  2. 8.1.1 Europe Oral Hypoglycemic Agents and Insulin Injection Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Oral Hypoglycemic Agents and Insulin Injection Sales by Country (2021-2026)
  4. 8.1.3 Europe Oral Hypoglycemic Agents and Insulin Injection Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Oral Hypoglycemic Agents and Insulin Injection Market Size by Country
  6. 8.2.1 Europe Oral Hypoglycemic Agents and Insulin Injection Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Oral Hypoglycemic Agents and Insulin Injection Market Size by Country (2021-2026)
  8. 8.2.3 Europe Oral Hypoglycemic Agents and Insulin Injection Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Oral Hypoglycemic Agents and Insulin Injection Sales by Country
  2. 9.1.1 Asia-Pacific Oral Hypoglycemic Agents and Insulin Injection Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Oral Hypoglycemic Agents and Insulin Injection Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Oral Hypoglycemic Agents and Insulin Injection Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Oral Hypoglycemic Agents and Insulin Injection Market Size by Country
  6. 9.2.1 Asia-Pacific Oral Hypoglycemic Agents and Insulin Injection Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Oral Hypoglycemic Agents and Insulin Injection Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Oral Hypoglycemic Agents and Insulin Injection Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Oral Hypoglycemic Agents and Insulin Injection Sales by Country
  2. 10.1.1 South America Oral Hypoglycemic Agents and Insulin Injection Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Oral Hypoglycemic Agents and Insulin Injection Sales by Country (2021-2026)
  4. 10.1.3 South America Oral Hypoglycemic Agents and Insulin Injection Sales Forecast by Country (2027-2032)
  5. 10.2 South America Oral Hypoglycemic Agents and Insulin Injection Market Size by Country
  6. 10.2.1 South America Oral Hypoglycemic Agents and Insulin Injection Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Oral Hypoglycemic Agents and Insulin Injection Market Size by Country (2021-2026)
  8. 10.2.3 South America Oral Hypoglycemic Agents and Insulin Injection Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Sales by Country
  2. 11.1.1 Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Market Size by Country
  6. 11.2.1 Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Oral Hypoglycemic Agents and Insulin Injection Value Chain Analysis
  2. 12.1.1 Oral Hypoglycemic Agents and Insulin Injection Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Oral Hypoglycemic Agents and Insulin Injection Production Mode & Process
  7. 12.2 Oral Hypoglycemic Agents and Insulin Injection Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Oral Hypoglycemic Agents and Insulin Injection Distributors
  10. 12.2.3 Oral Hypoglycemic Agents and Insulin Injection Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst